Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SH) announced plans for the company and its wholly-owned subsidiary Yangzhou Pharmaceutical Co., Ltd. to jointly invest 300 million yuan in constructing three new facilities on the company's southwestern land parcel. The projects include an export formulation plant, an anti-tumor synthesis plant, and an anti-tumor formulation plant.
Jiangsu Lianhuan Pharmaceutical will contribute 150 million yuan from self-raised funds to construct the export formulation plant, anti-tumor synthesis plant, and anti-tumor formulation plant along with corresponding production lines. The anti-tumor synthesis facility will house cytotoxic anti-tumor production lines (including purification, drying, and packaging processes) and non-cytotoxic anti-tumor synthesis lines. The anti-tumor formulation plant will contain oral cytotoxic anti-tumor drug production lines and oral non-cytotoxic anti-tumor drug production lines.
Concurrently, Yangzhou Pharmaceutical will invest 150 million yuan from its own capital to establish export formulation production lines and a supporting automated warehouse. This facility will incorporate hormone small-volume injection and freeze-drying production lines, hormone solid preparation lines, conventional small-volume injection and freeze-drying lines, general solid preparation lines, and related automated storage systems.
This strategic expansion represents significant progress for the company's future development, creating new growth opportunities. Within the core anti-tumor sector, the new synthesis and formulation facilities will strengthen the company's foothold in cancer therapeutics. The capacity upgrade aims to enhance large-scale manufacturing capabilities and supply chain resilience for related products, ultimately boosting competitiveness in China's anti-tumor pharmaceutical market.
Comments